Trials (Institut Paoli-Calmettes): Revision history

14 December 2025

• curprev 18:4018:40, 14 December 2025‎ Francine talk contribs‎ 318,022 bytes +186‎ No edit summary undo

6 December 2025

• curprev 12:4112:41, 6 December 2025‎ Lucas talk contribs‎ m 317,836 bytes +1,701‎ Update categories. undo

2 December 2025

• curprev 20:4720:47, 2 December 2025‎ Francine talk contribs‎ 316,135 bytes +48‎ No edit summary undo
• curprev 13:5913:59, 2 December 2025‎ Lucas talk contribs‎ m 316,087 bytes +43,119‎ Update categories. undo

4 January 2024

• curprev 18:0218:02, 4 January 2024‎ Francine talk contribs‎ 272,968 bytes −4‎ No edit summary undo
• curprev 18:0118:01, 4 January 2024‎ Francine talk contribs‎ 272,972 bytes +19‎ No edit summary undo
• curprev 18:0018:00, 4 January 2024‎ Francine talk contribs‎ 272,953 bytes −91‎ No edit summary undo
• curprev 17:5617:56, 4 January 2024‎ Francine talk contribs‎ 273,044 bytes −54‎ No edit summary undo
• curprev 17:5417:54, 4 January 2024‎ Francine talk contribs‎ 273,098 bytes +1‎ No edit summary undo
• curprev 17:5017:50, 4 January 2024‎ Francine talk contribs‎ 273,097 bytes −18‎ No edit summary undo
• curprev 17:4817:48, 4 January 2024‎ Francine talk contribs‎ 273,115 bytes −1‎ No edit summary undo
• curprev 17:4717:47, 4 January 2024‎ Francine talk contribs‎ 273,116 bytes −5‎ No edit summary undo
• curprev 17:4617:46, 4 January 2024‎ Francine talk contribs‎ 273,121 bytes +1,989‎ No edit summary undo
• curprev 17:2717:27, 4 January 2024‎ Francine talk contribs‎ 271,132 bytes +322‎ No edit summary undo
• curprev 17:1917:19, 4 January 2024‎ Francine talk contribs‎ 270,810 bytes +1,377‎ No edit summary undo
• curprev 17:0317:03, 4 January 2024‎ Francine talk contribs‎ 269,433 bytes +1,060‎ No edit summary undo

1 December 2023

• curprev 22:0422:04, 1 December 2023‎ Francine talk contribs‎ 268,373 bytes +268,373‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Institut Paoli-Calmettes page '''NCTID''': NCT04070443 '''Title''': Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase '''Study Summary''': The investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a stable..."